Tserebrovaskulyarnye rasstroystva na fone diffuznogo toksicheskogo zoba: kliniko-diagnosticheskie osobennosti i opyt primeneniya Korteksina

The study was aimed to the investigation of the features of cerebrovascular disorders in patients with diffuse toxic goiter (Graves' disease), as well as evaluation of the effectiveness of neuroprotector Cortexin in this category of patients. Patients were divided into 2 groups: group with hyperthyroidism (38 patients) with the manifest untreated diffuse toxic goiter, and group with medically induced euthyroidism (30 patients). Euthyroid patients were treated by an endocrinologist for at least 6 months. The control group (CG) consisted of 10 healthy individuals. All patients were additionally treated with Cortexin at a dose of 10 mg 2 times a day (morning and afternoon) for 10 days. It was concluded that the use of Cortexin in patients with cerebrovascular disorders against the background of Graves' disease significantly improves neurological and neuropsychological status, which in turn contributes to shorten the rehabilitation of this category of patients and improvement of their quality of life.

diffuse toxic goiter, euthyroidism, neuroprotectors, Cortexin